Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$49.88

0.94 (1.92%)

, PTCT

PTC Therapeutics

$7.55

-0.42 (-5.27%)

12:53
10/19/16
10/19
12:53
10/19/16
12:53

FDA official says Sarepta 'NOT a good model for other development programs'

In an October 18 slide presentation prepared for the NORD Summit Meeting, John Jenkins, director of the FDA's Office of New Drugs states: "A poorly planned and executed development program for a rare disease misuses valuable patient resources and serves to delay obtaining the knowledge required to understand the benefits and risks of a drug to support regulatory review and approval... Path taken by Sarepta NOT a good model for other development programs." Sarepta (SRPT) recently received approval for Exondys 51, its Duchenne muscular dystrophy treatment, despite criticism that it had not proven a true clinical benefit. In the wake of the medicine's controversial approval, market observers and analysts have debated whether drug candidates from PTC Therapeutics (PTCT) and BioMarin (BMRN) could benefit from the FDA's seemingly loosened approval standards and apparent desire to see Duchenne treatments on the market. Reference Link

SRPT

Sarepta

$49.88

0.94 (1.92%)

PTCT

PTC Therapeutics

$7.55

-0.42 (-5.27%)

BMRN

BioMarin

$85.40

-0.05 (-0.06%)

  • 19

    Oct

  • 27

    Oct

  • 06

    Nov

  • 29

    Nov

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

SRPT Sarepta
$49.88

0.94 (1.92%)

10/18/16
FBCO
10/18/16
INITIATION
Target $68
FBCO
Outperform
Sarepta initiated with an Outperform at Credit Suisse
Credit Suisse analyst Alethia Young initiated Sarepta with an Outperform and a $68 price target. The analyst has positive expectations on the US EXONDYS 51 launch, confidence of approval and IP settlement in Europe, and success with the Exon 53 program in mid-2017.
10/17/16
JANY
10/17/16
NO CHANGE
JANY
PTC's denial has negative read-through for BioMarin, says Janney Capital
Janney Capital noted that PTC Therapeutics' (PTCT) Translarna and Sarepta's (SRPT) Exondys 51 address non-overlapping DMD populations and there was an expectation of flexibility from the FDA following the conditional approval of Exondys 51. However, the FDA has denied the first appeal of the refuse to file letter regarding PTC's NDA for Translarna for the treatment of nonsense mutation DMD, which the firm said has potential negative read-through for BioMarin's (BMRN) attempt to rekindle Kyndrisa, which is a direct competitor to Sarepta's Exondys 51. The firm added that the news might positively impact reimbursement decisions for Exondys 51.
10/07/16
BARD
10/07/16
NO CHANGE
Target $102
BARD
Outperform
Anthem policy does not mean insurer not covering Sarepta drug, says Baird
Baird analyst Brian Skorney noted Anthem (ANTM) has categorized Sarepta (SRPT) Duchenne muscular dystrophy drug Exondys 51 as "not medically necessary" in a new coverage policy, but he cautions this "does not mean that Anthem is not covering the drug." The analyst explains that the policy means prior authorization requirements may be stricter, but he "highly doubts" that eligible patients will be denied coverage. Skorney, who adds that other large insurers appear to have favorable coverage for the drug, keeps an Outperform rating and $102 price target on Sarepta shares.
10/05/16
ADAM
10/05/16
NO CHANGE
Target $28
ADAM
Buy
Summit Therapeutics price target raised to $28 from $14 at Canaccord
Canaccord analyst Arinda Lee raised her price target on Summit Therapeutics (SMMT) to $28 from $14 following the announcement of its collaboration and licensing agreement with Sarepta Therapeutics (SRPT). The deal calls for Sarepta to gain EU commercialization rights to Summit's pipeline of oral utrophin modulators for all patients with Duchenne muscular dystrophy. Lee reiterated her Buy rating Summit Therapeutics shares.
PTCT PTC Therapeutics
$7.55

-0.42 (-5.27%)

09/20/16
JEFF
09/20/16
NO CHANGE
Target $7
JEFF
Hold
Jefferies thinks eteplirsen approval will have limited impact on PTC
Jefferies analyst Gena Wang believes yesterday's FDA approval of Sarepta Therapeutics' (SRPT) eteplirsen will have a limited impact on PTC Therapeutics (PTCT). While PTC's potential treatment for Duchenne muscular dystrophy ataluren is considered safe, the FDA approval of eteplirsen is mainly based on the marginal increase of dystrophin level and PTC does not have any dystrophin data from Phase 3, Wang tells investors in a research note. Eteplirsen's approval could pressure the FDA to reconsider the review progress of ataluren, but the final outcome would likely remain the same, the analyst contends. She keeps a Hold rating on PTC with a $7 price target. The stock closed yesterday up 21%, or $1.88, to $10.99.
10/03/16
BOFA
10/03/16
NO CHANGE
Target $15
BOFA
Buy
PTC Therapeutics price target raised to $15 from $9 at BofA/Merrill
BofA/Merrill analyst Tazeen Ahmad raised PTC Therapeutics' price target to $15 from $9 following partner Roche's recruitment for a trial it is conducting to investigate a potential treatment for Spinal Muscular Atrophy, or SMA, patients. Given this advancement, the analyst is raising his probability of approval to 30% from 20% in SMA and maintains his Neutral rating.
10/17/16
SBSH
10/17/16
NO CHANGE
Target $9
SBSH
Neutral
Citi says time running out for PTC Therapeutics in Europe
Citi analyst Joel Beatty says that while the FDA's denial of PTC Therapeutics' first appeal was widely expected, the major objection relating to the efficacy of Translarna by Europe's Committee for Medicinal Products for Human Use is more concerning. The move highlights that the CHMP is still not comfortable with the overall risk-benefit profile of Translarna ahead of an expected decision by year-end, Beatty tells investors in a research note. He sees heightened risk of Translarna's marketing authorization not being renewed in Europe and feels PTC's time is running out to alleviate CHMP's concerns. The analyst has a Neutral rating on the shares with a $9 price target. PTC is trading down 30%, or $3.94, to $9.34 in morning trading.
BMRN BioMarin
$85.40

-0.05 (-0.06%)

10/14/16
BARD
10/14/16
NO CHANGE
Target $115
BARD
Outperform
BioMarin hemophilia drug update encouraging, says Baird
Baird analyst Michale Ulz said he is encouraged by BioMarin's update on its Phase 1/2 study of its Hemophilia A drug, BMN-270. The analyst noted U.K. regulators approved continued enrollment in the gene-therapy study and the study was amended to allow dose optimization ahead of the Phase 2b study expected in 2017. Ulz reiterated his Outperform rating and $115 price target on BioMarin shares.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
09/21/16
LEER
09/21/16
NO CHANGE
LEER
Market Perform
Previous PTAB ruling remains overhang on Sarepta eteplirsen, says Leerink
Leerink analyst Joseph Schwartz notes that Sarepta (SRPT) has announced favorable Patent Trial and Appeal Board of the U.S. Patent and Trademark Office decisions in favor of its exon 51 and 53 composition of matter patent interference cases against BioMarin (BMRN). However, he points out that these rulings are subject to appeal and a previous ruling from the U.S. Patent Trial and Appeal Board, or PTAB, in favor of BioMarin's method of use patent remains an overhang on the commercialization of Sarepta's eteplirsen. The analyst reiterates a Market Perform rating on Sarepta's shares.

TODAY'S FREE FLY STORIES

NUE

Nucor

$62.83

1.97 (3.24%)

15:46
02/27/17
02/27
15:46
02/27/17
15:46
Options
Nucor call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKA

Roka Bioscience

$4.26

-0.18 (-4.05%)

15:44
02/27/17
02/27
15:44
02/27/17
15:44
Conference/Events
Roka Bioscience to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 29

    Mar

TESS

TESSCO

$14.05

-0.3 (-2.09%)

15:43
02/27/17
02/27
15:43
02/27/17
15:43
Hot Stocks
TESSCO signs deal with GEAR4 as exclusive U.S. distributor »

TESSCO Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LJPC

La Jolla

$19.87

1.65 (9.06%)

15:42
02/27/17
02/27
15:42
02/27/17
15:42
Recommendations
La Jolla analyst commentary  »

La Jolla price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 19

    Mar

CUR

Neuralstem

$3.86

0.16 (4.32%)

15:36
02/27/17
02/27
15:36
02/27/17
15:36
Hot Stocks
Breaking Hot Stocks news story on Neuralstem »

Tianjin Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WUBA

58.com

$32.46

0.49 (1.53%)

15:35
02/27/17
02/27
15:35
02/27/17
15:35
Options
58.com options imply 10.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

NURO

NeuroMetrix

$0.63

-0.0317 (-4.79%)

15:35
02/27/17
02/27
15:35
02/27/17
15:35
Conference/Events
NeuroMetrix to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

CGI

Celadon Group

$8.55

0.45 (5.56%)

, USAK

USA Truck

$9.00

0.14 (1.58%)

15:33
02/27/17
02/27
15:33
02/27/17
15:33
Hot Stocks
Celadon, USA Truck called best M&A targets as truckers seen consolidating »

Stephens argued that amid…

CGI

Celadon Group

$8.55

0.45 (5.56%)

USAK

USA Truck

$9.00

0.14 (1.58%)

HTLD

Heartland Express

$20.64

0.2 (0.98%)

KNX

Knight Transportation

$32.70

0.55 (1.71%)

SWFT

Swift Transportation

$22.09

0.35 (1.61%)

CVTI

Covenant Transportation

$20.06

0.05 (0.25%)

MRTN

Marten Transport

WERN

Werner

$27.80

0.45 (1.65%)

XPO

XPO Logistics

$51.41

1.01 (2.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

  • 02

    May

GLD

SPDR Gold Trust

$119.45

-0.25 (-0.21%)

15:32
02/27/17
02/27
15:32
02/27/17
15:32
Options
Aggressive short-term call spread in the SPDR Gold Fund »

Aggressive short-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGY

Stone Energy

$6.73

0.15 (2.28%)

, EQT

EQT Corporation

$60.73

0.785 (1.31%)

15:31
02/27/17
02/27
15:31
02/27/17
15:31
Hot Stocks
Stone Energy announces close of sale of Appalachia properties »

Stone Energy (SGY)…

SGY

Stone Energy

$6.73

0.15 (2.28%)

EQT

EQT Corporation

$60.73

0.785 (1.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXEL

Exelixis

$21.69

-0.05 (-0.23%)

15:20
02/27/17
02/27
15:20
02/27/17
15:20
Options
Exelixis options imply 12.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

$NSD

NASDAQ Market Internals

15:17
02/27/17
02/27
15:17
02/27/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
02/27/17
02/27
15:16
02/27/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$29.94

-0.25 (-0.83%)

15:14
02/27/17
02/27
15:14
02/27/17
15:14
Periodicals
GE sales process for Industrial Solutions may start in March, Bloomberg says »

Amid its continuing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

VIP

VimpelCom

$4.30

-0.04 (-0.92%)

15:11
02/27/17
02/27
15:11
02/27/17
15:11
Options
Higher option volume in Vimpel driven by poste-earnings puts »

Higher option volume in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VAC

Marriott Vacations

$96.51

-2.39 (-2.42%)

15:09
02/27/17
02/27
15:09
02/27/17
15:09
Conference/Events
Marriott Vacations management to meet with MKM Partners »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

TGT

Target

$66.95

0.435 (0.65%)

, AZO

AutoZone

$734.44

1.685 (0.23%)

15:06
02/27/17
02/27
15:06
02/27/17
15:06
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

TGT

Target

$66.95

0.435 (0.65%)

AZO

AutoZone

$734.44

1.685 (0.23%)

DPZ

Domino's Pizza

$185.90

-0.378 (-0.20%)

VRX

Valeant

$16.73

0.5499 (3.40%)

PAH

Platform Specialty Products

$13.19

0.14 (1.07%)

ENDP

Endo

$13.15

-0.24 (-1.79%)

DDD

3D Systems

$17.04

0.55 (3.34%)

SEAS

SeaWorld

$18.66

0.035 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 02

    Mar

  • 13

    Mar

  • 14

    Mar

  • 14

    Mar

  • 19

    Mar

  • 22

    Mar

  • 23

    Mar

  • 24

    Mar

PCLN

Priceline

$1,631.62

-5.64 (-0.34%)

, WDAY

Workday

$90.92

1.26 (1.41%)

15:05
02/27/17
02/27
15:05
02/27/17
15:05
Earnings
Notable companies reporting after market close »

Notable companies…

PCLN

Priceline

$1,631.62

-5.64 (-0.34%)

WDAY

Workday

$90.92

1.26 (1.41%)

PRGO

Perrigo

$84.39

-0.04 (-0.05%)

ALB

Albemarle

$92.74

-0.19 (-0.20%)

EXEL

Exelixis

$21.69

-0.05 (-0.23%)

RSPP

RSP Permian

$40.77

0.88 (2.21%)

FTR

Frontier Communications

$3.37

-0.02 (-0.59%)

CST

CST Brands

$48.37

0.02 (0.04%)

THC

Tenet

$22.36

0.365 (1.66%)

HTZ

Hertz

$19.86

-0.11 (-0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 02

    Mar

  • 13

    Mar

  • 14

    Mar

  • 16

    Mar

  • 20

    Mar

  • 21

    Mar

HTZ

Hertz

$19.87

-0.105 (-0.53%)

15:05
02/27/17
02/27
15:05
02/27/17
15:05
Options
Hertz options imply 18.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

15:00
02/27/17
02/27
15:00
02/27/17
15:00
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

MNK

Mallinckrodt

$54.42

1.04 (1.95%)

14:57
02/27/17
02/27
14:57
02/27/17
14:57
Conference/Events
Mallinckrodt management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 03

    Mar

INCY

Incyte

$131.21

9.26 (7.59%)

, SE

Acquired by ENB

14:55
02/27/17
02/27
14:55
02/27/17
14:55
Hot Stocks
Incyte to replace Spectra Energy in S&P 500 as of 2/28 open »

Spectra Energy (SE) is…

INCY

Incyte

$131.21

9.26 (7.59%)

SE

Acquired by ENB

ENB

Enbridge

$42.05

0.705 (1.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 06

    Mar

  • 14

    Mar

  • 01

    Apr

  • 19

    Apr

DDS

Dillard's

$56.99

-0.01 (-0.02%)

, ISIL

Intersil

14:55
02/27/17
02/27
14:55
02/27/17
14:55
Hot Stocks
Dillard's to replace Intersil in S&P 400 as of 2/28 open »

Renesas Electronics Corp.…

DDS

Dillard's

$56.99

-0.01 (-0.02%)

ISIL

Intersil

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WRK

WestRock

$53.69

0.26 (0.49%)

14:54
02/27/17
02/27
14:54
02/27/17
14:54
Conference/Events
WestRock management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

GIG

GigPeak

$3.10

0.03 (0.98%)

14:52
02/27/17
02/27
14:52
02/27/17
14:52
Hot Stocks
Gardner Lewis reports new 8.6% stake in GigPeak »

Shares of GigPeak spiked…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Apr

  • 05

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.